Search company, investor...


Founded Year



Series B | Alive

Total Raised


Last Raised

$940K | 18 days ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+90 points in the past 30 days

About PainDrainer

PainDrainer develops cloud-based applications for the self-management of chronic pain, using multilevel artificial intelligent systems. The company offers to deliver a disruptive tool based on advanced artificial intelligence (AI) algorithms that will meet the urgent clinical need for a novel treatment of chronic and non-malignant pain. PainDrainer was founded in 2018 and is based in Lund, Sweden.

Headquarters Location

Medicon Village bldg 301 Scheelevägen 2

Lund, 223 63,


Missing: PainDrainer's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: PainDrainer's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing PainDrainer

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PainDrainer is included in 1 Expert Collection, including Digital Health.


Digital Health

12,869 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Latest PainDrainer News

Paindrainer AB appoints Linda Nyberg as new Board Member

Mar 14, 2023

PainDrainer Tue, Mar 14, 2023 11:00 CET MEDICON VILLAGE, LUND SWEDEN – Paindrainer AB announces that Linda Nyberg will join the company’s Board of Directors. Linda Nyberg has a very broad experience from tech and life science scenes. She is currently the Chief Communications Officer at Novatron Fusion Group AB and is member of the Board for C Green Technology AB and Flarie AB, a digital entertainment platform. Paindrainer AB is a digital therapeutics (DTx) company developing digital platforms and applications contributing to health and well-being. The Paindrainer app is the first evidence based digital tool demonstrating improved quality of life in patients suffering from chronic pain. The solution is powered by a proprietary Artificial Neural Network (ANN) and is fully adaptive to each chronic pain patient i.e., 360o patient-centricity©. Linda has a solid background in media and has worked in corporate communications, public affairs, crisis communication, including marketing for multinational listed companies primarily in the health sector. She has held several leading roles in companies, such as Essity, listed on Nasdaq, Apoteket AB, AniCura AB and Bactiguard AB, the latter a Swedish med-tech company. “I am honored to join Paindrainer AB as a Board Member. Digitalization and patient empowerment are two topics close to my heart. It's evident that digital therapeutic platforms can add significant value and help offload the traditional healthcare systems. Paindrainer is in a very exciting phase, and I hope to be able to contribute to further success with my experience from the teach and health areas”, says Linda Nyberg. “I am very happy to welcome Linda to the board. Her vast market and communication experience from both life science and tech is a perfect background to PainDrainer when we now are entering into an international commercial phase. Her personal engagement for digitalization and patient empowerment will highly contribute to the company and with Linda on board I am very pleased with the composition of competencies in the board”, says Prof. Carl Borrebaeck, Chairman of the Board. Linda Nyberg is also part of the Advisory Board of The Techarena, UNHCR for Sweden and the Swedish Teacher’s Award, Lärargalan. For more information, please contact: Carl Borrebaeck About Paindrainer AB Paindrainer AB is a company developing digital platforms and applications contributing to health and well-being. Paindrainer was founded in 2018 by Prof. Carl Borrebaeck, Dr. Maria Rosén Klement, and Göran Barkfors (IT specialist). The idea was born when Maria, after participating in several pain rehabilitation programs, realized that the pain is affected by more factors than the human brain can keep track of, since all days are different. PainDrainer® uses advanced calculations based on artificial intelligence to coach the user in planning their day not to exceed a certain pain level, and to ensure that there is energy left for activities highly valued. Paindrainer® has clinical evidence, is based on Acceptance and Commitment Therapy (ACT), self-management and artificial intelligence (AI). The app is CE Class 1 Medical Device certified and is an FDA Mobile Medical Device Class 1 with exemption.

PainDrainer Frequently Asked Questions (FAQ)

  • When was PainDrainer founded?

    PainDrainer was founded in 2018.

  • Where is PainDrainer's headquarters?

    PainDrainer's headquarters is located at Medicon Village bldg 301, Lund.

  • What is PainDrainer's latest funding round?

    PainDrainer's latest funding round is Series B.

  • How much did PainDrainer raise?

    PainDrainer raised a total of $2.97M.

  • Who are the investors of PainDrainer?

    Investors of PainDrainer include Almi Invest, Christian Jansson and KappAhl.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.